In September 2019, the Company's Board of Directors (the Board) adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board and is generally four years from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. Pursuant to the evergreen provision, on January 1, 2025, an additional 705,613 shares of the Company's common stock became available for issuance under the 2019 Plan. As of June 30, 2025, 2,533,057 shares of the Company's common stock remained available for future awards under the 2019 Plan.

As of June 30, 2025, all of the 1,679,624 outstanding RSUs were unvested. The fair value of RSUs vested in the six months ended June 30, 2025 and 2024 was $1.3 million and $0.5 million, respectively. The weighted average grant date fair value for RSUs granted in the six months ended June 30, 2025 and 2024 was $3.97 and $1.89 per unit, respectively. As of June 30, 2025, total unrecognized compensation cost related to RSUs was $4.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.8 years.


	Number of Options	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2024	489,296	$	8.39	6.53	$	370
Granted	169,570	$	4.68
Exercised	(108)	$	0.37

Expired	(94,317)	$	8.79
Outstanding, June 30, 2025	564,441	$	7.21	6.71	$	1,222
Vested and expected to vest, June 30, 2025	564,441	$	7.21	6.71	$	1,222
Options exercisable, June 30, 2025	379,524	$	8.54	5.28	$	741

There were 169,570 and 55,500 stock options granted in the six months ended June 30, 2025 and 2024, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The aggregate intrinsic value of options exercised during each of the six months ended June 30, 2025 and 2024 was negligible. As of June 30, 2025, total unrecognized compensation cost related to option awards was $0.6 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.7 years.

In September 2019, the Board adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Board. The ESPP permits participants to purchase shares of the Company's common stock through payroll deductions of up to 20.0% of their eligible compensation. The number of shares of the Company's common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) 1.0% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. Pursuant to the evergreen provision, on January 1, 2025, an additional 176,403 shares of the Company's common stock became available for issuance under the ESPP. As of June 30, 2025, 619,593 shares of the Company's common stock remained available for issuance under the ESPP. During the six months ended June 30, 2025, a total of 80,554 shares of the Company's common stock were issued under the ESPP.